Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Nov 16 2023

Full Issue

Viewpoints: AI May Be The Key To Diagnosing Rare Diseases; Standard Drug Tests Miss Fentanyl And More

Editorial writers delve into AI, drug tests, safe injection sites and more.

The Washington Post: Can AI Solve Medical Mysteries? It's Worth Finding Out

It’s in the diagnosis of rare diseases — which afflict an estimated 30 million Americans and hundreds of millions of people worldwide — that AI could almost certainly make things better. “Doctors are very good at dealing with the common things,” says Isaac Kohane, chair of the department of biomedical informatics at Harvard Medical School. “But there are literally thousands of diseases that most clinicians will have never seen or even have ever heard of.” (Bina Venkataraman, 11/15)

Scientific American: To Treat Overdose Patients Now, Hospitals Must Test For More Kinds Of Drugs 

Hospitals link people to treatment in their time of greatest need. That includes drug overdoses, which now kill more than 100,000 people in the U.S. every year. However, the standard hospital urine drug tests often do not detect fentanyl, which today is the leading cause of fatal overdoses, or other “synthetic” substances. (Eric D. Wish, Amy Billing and Erin Artigiani, 11/15)

The New York Times: Safe Injection Sites Don’t Lead To More Crime, New Study Finds 

Over 100,000 Americans now die from drug overdoses annually. To combat this crisis in New York City and save lives, Mayor Bill de Blasio decided to support an initiative rife with controversy: In November 2021, his government allowed OnPoint, a nonprofit, to open two overdose prevention centers, where people with addictions can inject or smoke drugs like opioids and stimulants under medical supervision to reduce the risk of overdose death. (Maia Szalavitz, 11/16)

CNN: Fentanyl Is A Poison In The US-China Relationship

Fentanyl and other synthetic opioids kill tens of thousands of young Americans a year, and the compound is helping to poison the US relationship with China. It was one of the issues on the table as the two leaders of the world’s most powerful economies, Chinese leader Xi Jinping and US President Joe Biden, met outside San Francisco on Wednesday. (Peter Bergen, 11/15)

The New York Times: With Covid, Is It Really Possible To Say We Went Too Far? 

In 2020, many Americans told themselves that all it would take to halt the pandemic was replacing the president and hitting the “science button.” In 2023, it looks like we’re telling ourselves the opposite: that if we were given the chance to run the pandemic again, it would have been better just to hit “abort” and give up. (David Wallace-Wells, 11/15)

Stat: How Depression Has Changed 30 Years After ‘Listening To Prozac’

In 1993, I published “Listening to Prozac,” a book that grew out of my clinical experience prescribing what was then a new class of medications, ones thought to moderate depression through their effect on the way that the brain handles the neurotransmitter serotonin. Some of my patients had reported marked favorable reactions to the drugs — first Prozac and, soon after, Zoloft. On medication, the patients were more confident, less anxious, and less pessimistic. (Peter D. Kramer, 11/16)

Stat: A Daunting Task: Navigating Dual Medicare, Medicaid Eligibility

Three months ago, my aunt Margaret had a stroke. Days before, she was repainting her bathroom and driving herself. Now, she needs help with dressing and getting in and out of bed, and our family is grappling with the fact that this fiercely self-sufficient woman will never live independently again. This health crisis has been compounded at every turn by failures of the health care system — failures that are particularly infuriating to me because I have devoted my life to solving these very problems. (Dawn Alley, 11/16)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF